A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Syndax Pharmaceuticals, Inc
The purpose of this study is to find the best dose of revumenib taken with other cancer drugs, known as chemotherapy, and to find out what side effects happen after you take this study drug. It will also see how fast revumenib goes through your body (from when you take it in your mouth to when you can’t see it in your blood). This is called pharmacokinetics
Enrollment Form
This study is currently enrolling.